Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
05 January 2022 - 12:00AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company
is scheduled to participate in the upcoming 40th Annual J.P. Morgan
Healthcare Conference. Company executives will provide a business
overview and update on the company’s pipeline programs.
Details
Event |
40th Annual J.P. Morgan Healthcare Conference |
Location |
Virtual |
Date |
Monday, January 10, 2022 |
Time |
3:00 p.m.-3:40 p.m. Eastern Time |
A live webcast of the event will be available on the Investors
& News section of the Ascendis Pharma website at
https://ascendispharma.com. A webcast replay will be available on
the site shortly after conclusion of the event and will stay
available for 30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative platform technology to build a leading,
fully integrated biopharma company focused on making a meaningful
difference in patients’ lives. Guided by its core values of
patients, science and passion, the Company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark, and has
additional facilities in Heidelberg and Berlin, Germany; Palo Alto
and Redwood City, California; and Princeton, New Jersey. Please
visit www.ascendispharma.com to learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its platform technology to build a leading, fully
integrated biopharma company, and (ii) Ascendis’ use of its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Ascendis makes, including the following: dependence on third
party manufacturers and distributors to supply TransCon hGH, and
other study drug for commercial sales in the U.S. and clinical
studies; unforeseen safety or efficacy results in its oncology
programs, TransCon hGH, TransCon PTH and TransCon CNP or other
development programs; unforeseen expenses related to
commercialization of lonapegsomatropin-tcgd in the U.S., the co-pay
program, and the further development of TransCon hGH, expenses
related to the development and potential commercialization of its
oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or
other development programs, selling, general and administrative
expenses, other research and development expenses and Ascendis’
business generally; delays in the development of its oncology
programs, TransCon hGH, TransCon PTH and TransCon CNP or other
development programs related to manufacturing, regulatory
requirements, speed of patient recruitment or other unforeseen
delays; dependence on third party manufacturers to supply study
drug for planned clinical studies; Ascendis’ ability to obtain
additional funding, if needed, to support its business activities
and the effects on its business from the worldwide COVID-19
pandemic. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
Ascendis’ business in general, see Ascendis’ Annual Report on Form
20-F filed with the U.S. Securities and Exchange Commission (SEC)
on March 10, 2021 and Ascendis’ other future reports filed with, or
submitted to, the SEC. Forward-looking statements do not reflect
the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the Company
logo, TransCon, and SKYTROFA are trademarks owned by the Ascendis
Pharma Group. © January 2022 Ascendis Pharma A/S.
Investor Contacts: |
Media
Contact: |
Tim Lee |
Melinda Baker |
Ascendis Pharma |
Ascendis Pharma |
+1 (650) 374-6343 |
+1 (650) 709-8875 |
tle@ascendispharma.com |
media@ascendispharma.com |
|
|
Patti Bank |
|
ICR Westwicke |
|
+1 (415) 513-1284 |
|
patti.bank@westwicke.com |
|
ir@ascendispharma.com |
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2023 to Apr 2024